July 19, 2018 10:23 AM EDT
R&D

In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

Brittany Meiling

It’s good news for Al­ler­gan and Mol­e­c­u­lar Part­ners’ wet AMD drug. The duo an­nounced Thurs­day that abic­i­par has met its end­points in two Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times